Cancer Immunotherapy Winter School (CIWS)

癌症免疫治疗冬季学校（CIWS）

• 批准号: 10391811
• 负责人: Catherine M. Bollard
• 金额: $ 3万
• 依托单位: SOCIETY FOR IMMUNOTHERAPY OF CANCER, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10391811
• 关键词: Accreditation; Address; Advocate; Area; Award; Biological Markers; Cancer Patient; Charge; Clinical; Clinical Trials; Clinical Trials Design; Combined Modality Therapy; Continuing Education; Data Analyses; Development; Discrimination; Education; Educational Materials; Educational process of instructing; Emergency Department Physician; Ensure; Faculty; Feedback; Fees; Foundations; Funding; Future; Government; Grant; Health Professional; Healthcare; Immunology; Immunotherapy; Industry; International; Joints; Knowledge; Leadership; Learning; Location; Logistics; Medical; Mentorship; Methods; Mission; Modality; Nurses; Oncologist; Participant; Patient-Focused Outcomes; Patients; Persons; Pharmacists; Physicians; Process Assessment; Psychological reinforcement; Research; Schools; Science; Scientific Advances and Accomplishments; Scientist; Self-Direction; Societies; Structure; Teaching Method; Translations; Travel; Underrepresented Populations; United States; United States National Institutes of Health; austin; cancer care; cancer immunotherapy; cancer site; career; career networking; clinical application; continuing medical education; cost; design; educational atmosphere; experience; improved; innovation; insight; meetings; member; peer; programs; success; technology validation; translational physician; translational scientist; tumor immunology

4.0 PROJECT SUMMARY/ABSTRACT Established in 1984, the Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. The mission of SITC is to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. At the forefront of SITC’s educational charge is the Cancer Immunotherapy Winter School (CIWS) program. The 2022 program in Austin, TX will focus on delivering a program designed to enable basic, clinical, or translational scientists and clinicians from the entire cancer care team including those from diverse and underrepresented groups in biomedical sciences, to advance scientific discoveries and clinical applications of tumor immunology and cancer immunotherapy. This comprehensive, five-day accredited CME-/CNE-/CPE-/MOC-certified program will provide a deep understanding of the core principles of tumor immunology, cancer immunotherapy and developing areas in the field. With 51 topics including foundational immunology, clinical trial design, combination therapies, biomarker integration and data analysis, attendees have a number of session types (all- attendee, breakout, research/clinical tracks) tailored to maximize learning opportunities and styles through selection of sessions most relevant to their educational needs. This allows for many opportunities of personalized interaction between attendees and experts. Attendees, through small group sessions and networking roundtables, will expand their professional network, developing new relationships with faculty and other thought leaders. These hands-on sessions will provide valuable networking and mentorship opportunities, and poise questions from their own experiences. Designed and approved by experts across the healthcare spectrum—clinical physicians, nurses, pharmacists, emergency physicians, and patient advocates—establishes that all points of view are incorporated. For attendees of in-person courses, enduring materials are available following the program and will serve as reinforcement of their learnings and allow access to other concurrent sessions they could not attend. Materials are available to the public six months later at a nominal fee. SITC, program organizers, and faculty certifies the CIWS is open to all who wish to attend and it is a safe and respectful learning environment free from all forms of discrimination and harassment. Low registration rates, travel awards, ADA-compliant facilities, and a centralized location ensures that obstacles do not stand in the way of physicians’ knowledge and eventual use of these revolutionary treatments. SITC is uniquely poised to hold this premier, educational option for all healthcare professionals and every type of learner. NIH support for this program will allow for continued educational and professional advancement for the entire cancer care team, in addition to networking opportunities with peers and leaders in the field.

4.0项目摘要/摘要 癌症免疫治疗学会(SITC)成立于1984年，是世界领先的会员推动 专门致力于通过推动科学和技术进步来改善癌症患者预后的组织 肿瘤免疫治疗的应用。SITC的使命是通过以下方式改善癌症患者的预后 推动癌症免疫学和免疫治疗的科学、发展和应用 互动/整合、创新、翻译和领域领导的核心价值观。站在…的最前列 SITC的教育任务是癌症免疫疗法冬季学校(CIWS)计划。2022年计划在 德克萨斯州奥斯汀将专注于提供一个旨在使基础、临床或翻译科学家和 来自整个癌症护理团队的临床医生，包括来自不同和代表性不足的群体的医生 生物医学，以促进肿瘤免疫学和临床应用的科学发现和临床应用 癌症免疫疗法。这一为期五天的综合认证CME-/CNE-/CPE-/MOC认证计划将 深入了解肿瘤免疫学、癌症免疫治疗和 该领域的发展中地区。有51个主题，包括基础免疫学，临床试验设计， 综合疗法、生物标记物集成和数据分析，与会者有多种会议类型(所有- 与会者、分组讨论、研究/临床跟踪)，旨在通过以下方式最大化学习机会和风格 选择与他们的教育需求最相关的课程。这允许许多机会 与会者和专家之间的个性化互动。与会者，通过小组会议和 网络圆桌会议，将扩大他们的专业网络，与教职员工和 其他思想领袖。这些实践课程将提供有价值的网络和指导 机会，并从自己的经历中沉着地提出问题。由世界各地的专家设计和批准 医疗保健领域-临床医生、护士、药剂师、急诊医生和患者 倡导者-确立所有观点都被纳入其中。对于面对面课程的参与者，持久 课程结束后将提供材料，作为他们学习的加强，并允许 访问他们无法参加的其他并发会议。材料在六个月后向公众开放 象征性收费。SITC、项目组织者和教职员工证明CIWS对所有希望参加的人开放 这是一个安全和尊重的学习环境，没有任何形式的歧视和骚扰。低 注册率、旅行奖励、符合ADA的设施和集中的位置确保了障碍 不妨碍医生了解和最终使用这些革命性的治疗方法。SITC是 独一无二地准备为所有医疗保健专业人员和各种类型的人举办这一顶级的教育选项 学习者。NIH对这一计划的支持将允许继续教育和职业发展 整个癌症护理团队，以及与该领域的同行和领导者建立联系的机会。